Printer Friendly

ACLARA and Genentech Expand eTag(TM) Assay Collaboration; First Collaboration Milestone in ACLARA Discovery Partners Program.

ACLARA BioSciences today announced the expansion of the eTag(TM) assay collaboration with Genentech, Inc. under ACLARA's Discovery Partners program. The expansion follows the successful achievement of an important milestone in which ACLARA designed a customized eTag assay that measured specific receptor binding and signaling events.

Under the terms of the agreement, which was initiated in mid-2002, Genentech paid ACLARA an undisclosed success fee in late 2002, and has now agreed to further expand the research. The terms of the expanded collaboration include certain fees payable by Genentech, including success fees payable upon completion of specified technical milestones.

"We are extremely excited about this success in our Discovery Partners program as it is the first external validation of the eTag assay technology for the identification of receptor activation and downstream signaling pathways. These are two of our most innovative and promising eTag assay applications," commented Thomas G. Klopack, ACLARA's chief executive officer. "We look forward to the expansion of our relationship with Genentech, and also to the broader commercialization of these important eTag applications."

About the eTag Assay System and Discovery Partners Program

The eTag Assay System is a high performance, high throughput system for the study of 10s to 100s of genes, proteins and cell-based antigens across thousands of samples. The system makes it possible for researchers to adopt a systems biology approach towards studies of gene expression, protein expression, and for applications such as cell signaling and pathway activation, protein-protein interaction and cell receptor binding.

The system uses ACLARA's proprietary eTag reporters to multiplex the analysis of genes and/or proteins from the same sample. Specific molecular binding events result in the release of electrophoretically distinct eTag reporters, which are then resolved to provide precise, sensitive quantitation of multiple analytes-directly from cell lysates.

For applications that require a much more involved level of customization and provide breakthrough discoveries, ACLARA is structuring collaborations that allow companies access to eTag technology focused on their specific applications. Through the Discovery Partners Program, ACLARA's partners can use ACLARA's proprietary techniques to discover and adopt novel targets, lead compounds, protein and antibody therapeutics, and diagnostics.

Conference Call

The company plans to discuss this development along with financial results for the first quarter of 2003 on a conference call scheduled for Wednesday April 30, 2003 at 5 p.m. Eastern/2 p.m. Pacific. Interested parties may participate in the conference call by calling 888-277-8128 domestic, or 973-582-2729 international, or you may listen via live audio broadcast over the Internet by going to the Conference Calls link on the ACLARA Investor Relations website available at For those unable to participate on the live call, a 24-hour replay will be available for seven days after the call at, or by calling 877-519-4471 and giving the following pass code: 3887175.


ACLARA BioSciences, Inc. is developing advanced tools for drug discovery, genomics and proteomics using its proprietary eTag assay chemistries. The Company's products allow researchers to have decision-critical information for drug development, which previously was difficult or impossible to obtain. The solution-phase eTag Assay System is cost-effective, easy-to-use and flexible, and enables highly accurate and precise analysis of genes and/or proteins from limited biological samples. For multiplexed gene expression, ACLARA uses eTag Multiplex Invader(R) Assays, which incorporate Invader technology and Cleavase(R) enzyme and are licensed for use from Third Wave Technologies, Inc. Importantly, researchers can use their existing instrument platforms to perform eTag analyses. More information on ACLARA can be obtained on the Company's web site at

Forward Looking Statement

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for ACLARA from those projected. Those factors include risks and uncertainties relating to technological approaches of ACLARA and its competitors, the performance of the Company's products, product development, manufacturing, market acceptance, development and commercialization efforts, the ability to manage operating expenses, the ability to attract and retain key personnel, successful establishment of and performance under collaborative and commercial agreements including accomplishment of technical milestones and completion of negotiations for further collaborations, adoption of its technologies, the systems biology and molecular medicine approaches by pharmaceutical and biotechnology companies, and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission.


ACLARA BioSciences, eTag, and the ACLARA logo are trademarks of ACLARA BioSciences, Inc. Invader and Cleavase are registered trademarks of Third Wave Technologies, Inc.

CONTACT: Alfred Merriweather. VP, Finance and CFO of ACLARA, +1-650-210-1200, or

Web site:
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Apr 30, 2003
Previous Article:Laserscope Receives Patent for Its GreenLight Laser.
Next Article:VERITAS Software Corporation to Host Analyst Day at Annual Users Conference.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters